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Introduction {#sec1}
============

Dendritic cells (DCs) link innate and adaptive immunity by recognizing pathogens through pattern recognition receptors such as Toll-like receptors (TLRs) and recruiting diverse immune cells to orchestrate antigen (Ag)-specific adaptive responses ([@bib39], [@bib50]). Classical or conventional DCs (cDCs) are specialized Ag-presenting cells with a characteristic dendritic morphology, high major histocompatibility complex (MHC) class II expression, and a unique capacity for priming naive T cells. Upon Ag capture, cDCs upregulate chemotactic receptors such as CCR7, migrate from tissues into the T cell areas of regional lymphoid organs, secrete cytokines and chemokines, and present Ag to Ag-specific T cells. As such, cDCs hold great promise as cellular vaccines for eliciting Ag-specific immune responses, in particular to tumor antigens ([@bib36]).

In the mouse, cDCs are comprised of two main subsets: CD8^+^/CD103^+^ cDCs capable of Ag cross-presentation to CD8^+^ T cells and CD11b^+^ cDCs specialized in the presentation of exogenous Ag to CD4^+^ T cells ([@bib30], [@bib31], [@bib47]). Both subsets are conserved in humans ([@bib18]) and have recently been designated as cDC1 and cDC2, respectively ([@bib16]). All DCs, including cDCs and the related lineage of interferon-producing plasmacytoid DCs (pDCs), develop in the bone marrow (BM) in a process driven mainly by the cytokine FLT3 ligand (FLT3L). Progenitors committed to cDC subsets (pre-DCs) exit the BM and undergo terminal differentiation in peripheral lymphoid organs and tissues. The development of DC subsets is driven by several transcription factors, such as IRF8, which is absolutely required for cDC1 differentiation in mice ([@bib1], [@bib48]) and in humans ([@bib4], [@bib17]). Additional factors, such as BATF3 and other BATF family members, cooperate with IRF8 to facilitate optimal development of cDC1s ([@bib20], [@bib33]). In addition to these cell-intrinsic factors, terminal cDC differentiation in the periphery is guided by tissue-specific signals, such as lymphotoxin-β and Notch.

Notch is an evolutionarily conserved pathway of cell-cell communication that informs cells of their surroundings and, thereby, guides their differentiation. Vertebrate Notch receptors (NOTCH1--4) transmit signals from membrane-bound ligands of the Delta-like (DL) and Jagged (Jag) families through the common transcription factor CSL (also called RBPJ). Notch signaling plays an essential role in the development of immune cell types that differentiate in distinct anatomical niches. For instance, DL4-NOTCH1 and DL1-NOTCH2 signaling is required for the specification of T cells in the thymus and of marginal zone (MZ) B cells in the spleen, respectively ([@bib41]). Indeed, co-culture of stem/progenitor cells with a murine stromal cell line OP9 expressing DL1 (OP9-DL1) has become a standard approach to generate T cells in vitro ([@bib46], [@bib32]). Using DC-specific gene targeting, we have established the role of NOTCH2 receptor signaling in the differentiation of a cDC2 subset in the spleen and intestine ([@bib6], [@bib25]). In particular, splenic cDC2 contains a lymphotoxin-β- and NOTCH2-RBPJ-dependent Esam^hi^ subset that is required for optimal CD4^+^ T cell priming. These studies also revealed the reduction of Notch2-deficient splenic CD8α^+^ cDC1s ([@bib25]), which was subsequently ascribed to their impaired differentiation and aberrant phenotype ([@bib45]). Finally, DL1 expressed on fibroblasts has been identified as the relevant ligand of NOTCH2 on splenic cDCs ([@bib12]). Thus, NOTCH2 signaling mediated by DL ligands on stromal cells controls the phenotypic and functional differentiation of both cDC subsets.

Because primary DCs (particularly cDC1s) are rare *in vivo*, their study and translational applications require methods to generate functional DC subsets *in vitro*. Commonly used cultures of primary BM with the cytokine granulocyte-monocyte colony-stimulating factor (GM-CSF) produce a mixture of cDC2-like cells and macrophages ([@bib19]) but no cDC1s. Cultures of murine BM supplemented with the physiological cytokine FLT3L produce a mixture of pDCs, cDC2s and cDC1-like cells ([@bib34]). The latter express appropriate transcription factors, including IRF8, but have an abnormal phenotype, including a lack of key cDC1 markers (e.g., CD8α, CD103, and Dec205) and aberrant expression of cDC2 markers (e.g., CD11b). Human hematopoietic stem and progenitor cells cultured with FLT3L and other cytokines and/or stromal cells can produce CD141^+^ cDC1s with the expected expression profile and *in vitro* functional properties ([@bib3], [@bib23], [@bib37], [@bib38]). However, the yield of cDC1s has been very low in all reported protocols. Thus, new approaches are necessary to produce the full spectrum and high numbers of fully differentiated DCs, particularly of functional cDC1s.

Given the important role of Notch signaling in cDC differentiation *in vivo*, we hypothesized that it would facilitate cDC differentiation *in vitro*. We now report that combination of FLT3L-driven differentiation of murine hematopoietic progenitors with the well-established OP9-DL1 system produces optimally differentiated cDC subsets, including *bona fide* CD8α^+^ Dec205^+^ cDC1. The resulting cDC1s showed improved migration properties and superior T cell cross-priming capacity *in vivo*. Furthermore, co-culture of human hematopoietic progenitors with OP9-DL1 enhanced the generation of functional human cDC1s. These results emphasize the key role of Notch signaling in terminal cDC differentiation and facilitate the generation of functional cDC1s for translational applications.

Results {#sec2}
=======

Notch Signaling Enables cDC1 Differentiation of Immortalized DC Progenitors {#sec2.1}
---------------------------------------------------------------------------

To optimize DC production *in vitro*, we initially studied the differentiation of DC progenitors that were conditionally immortalized with the estrogen-dependent HoxB8 oncogene ([@bib42]). In this system, progenitors can be grown indefinitely in the presence of FLT3L and estrogen, whereas estrogen withdrawal induces spontaneous FLT3L-driven DC differentiation within ∼7 days. Although HoxB8-FL (FLT3L) cells were originally reported to produce all DC subsets, we never observed the production of CD24^+^ or CD8α^+^ cDC1s from the original HoxB8-FL line or from any newly derived lines ([Figure 1](#fig1){ref-type="fig"}A). To mimic Notch signals received by committed cDC progenitors *in vivo*, we differentiated HoxB8-FL cells for 3 days to initiate DC development and then plated them on a monolayer of OP9-DL1 cells or control GFP-transduced OP9 cells for the last 4 days of culture. Control OP9 cells inhibited the development of B220^+^ pDCs and yielded only CD11b^hi^ CD24^−^ CD8α^−^ cDC2s in lower numbers ([Figure 1](#fig1){ref-type="fig"}A and data not shown). Co-culture with OP9-DL1 largely abolished pDC development and reduced the yield of cDC2s; however, it induced the generation of a distinct cDC subset with the CD11b^−^ CD24^+^ CD8α^+^ phenotype of cDC1s ([Figures 1](#fig1){ref-type="fig"}A and 1B).Figure 1DL1-NOTCH2 Signaling Induces Differentiation of cDC1s from a DC Progenitor Cell LineThe HoxB8-FL cell line was induced to differentiate *in vitro* by estrogen withdrawal in the presence of FLT3L alone (FL), FLT3L with control OP9 cells (FL+OP9), or FLT3L with OP9 cells expressing the Notch ligand DL1 (FL+Notch). OP9 cells were added on day 3, and HoxB8-FL cells were analyzed on day 7 of differentiation.(A) Representative staining plots of differentiated HoxB8-FL cells. The top row shows total live cells with B220^+^ MHC class II^lo^ pDCs and B220^−^ MHC class II^hi^ cDCs highlighted; the other rows show gated cDCs with CD11b^hi^ cDC2s and CD11b^lo/−^ cDC1s highlighted.(B) The subset composition of differentiated HoxB8-FL cells. Shown are fractions of pDCs (of total live cells) and cDC subsets (of gated cDCs) and the absolute number of these subsets per 10^5^ initial undifferentiated cells. Data represent mean ± SD of 6 parallel cultures, representative of 3 experiments.(C) The effect of NOTCH2 blockade on HoxB8-FL cell differentiation. HoxB8-FL cells were differentiated in FL+Notch cultures in the presence of anti-NOTCH2 blocking Ab (anti-N2) at 50 ng/ml (gray open bars) or 500 ng/ml (gray textured bars); the fractions of DC subsets are shown as above. Data represent mean ± SD of 5 parallel cultures.(D) The effect of Notch ligands on HoxB8-FL cell differentiation. HoxB8-FL cells were differentiated in co-cultures with OP9 cells expressing the Notch ligand DL1 or DL4; the fractions of DC subsets are shown as above. Data represent mean ± SD of 6 parallel cultures.Statistical significance: ^∗∗∗∗^p \< 0.0001; ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ns, not significant.

To confirm that the observed DL1-driven cDC1 generation is NOTCH2-dependent, we used an antibody (Ab) that blocks the activation of NOTCH2 (anti-N2) ([@bib52]). The administration of this anti-N2 Ab *in vivo* recapitulated the effects of DC-specific NOTCH2 blockade, including ablation of splenic Esam^hi^ cDC2s and of intestinal CD11b^+^ CD103^+^ cDCs and loss of CD8α^+^ splenic cDC1s ([Figure S1](#mmc1){ref-type="supplementary-material"} and data not shown). The addition of anti-N2 to HoxB8-FL co-cultures with OP9-DL1 did not rescue pDC loss ([Figure 1](#fig1){ref-type="fig"}C), further suggesting that this loss is caused by OP9 cells independent of DL1 expression. On the other hand, anti-N2 reduced the development of cDC2s and largely abolished the development of cDC1s ([Figure 1](#fig1){ref-type="fig"}C). To test the function of NOTCH2 ligands, we used OP9 cells transduced with DL4 (OP9-DL4), which are as efficient as OP9-DL1 in driving T cell development ([@bib32]). We found that OP9-DL4 were able to induce cDC1 differentiation of HoxB8-FL cells, but less efficiently than OP9-DL1 ([Figure 1](#fig1){ref-type="fig"}D). Collectively, these data show that DL1-NOTCH2 signaling can elicit *de novo* generation of cDC1s from immortalized DC progenitors.

Notch Signaling Induces Optimal cDC1 Differentiation of BM Progenitors {#sec2.2}
----------------------------------------------------------------------

Having established the OP9-DL1 co-culture system of DC differentiation, we applied it to the cultures of primary BM. Total BM cells were either cultured for 7 days using a standard DC differentiation protocol in FLT3L-containing medium or transferred on day 3 to monolayers of OP9-DL1 in the continued presence of FLT3L (hereafter referred to as FL or FL-Notch cultures, respectively). As described previously ([@bib34]), DCs generated in FL cultures (DC^FL^) comprised B220^+^ pDCs, CD11b^+^ CD24^−^ cDC2s, and CD11b^+/low^ CD24^+^ cDC1-like cells ([Figure 2](#fig2){ref-type="fig"}A). Co-culture with control OP9 cells impaired the generation of pDCs and cDC1-like cells, yielding primarily cDC2s ([Figures 2](#fig2){ref-type="fig"}A--2C). In contrast, co-culture with OP9-DL1 inhibited pDC but not cDC development; moreover, the resulting DC population (DC^FL-Notch^) contained two fully resolved subsets, including a distinct CD11b^−^ CD24^+^ cDC1 population that expressed Dec205 and CD8α ([Figures 2](#fig2){ref-type="fig"}A--2C). In contrast to cDC1-like cells from FL cultures (cDC1^FL^), CD24^+^ cDC1s from FL-Notch cultures (cDC1^FL-Notch^) downregulated CD11b, acquired expression of Dec205 and CD8α, and upregulated CD103 ([Figure 2](#fig2){ref-type="fig"}D). Staining for additional subset markers revealed a similarly improved resolution of the two cDC subsets in FL-Notch cultures ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In particular, cDC2^FL^ expressed low levels of the cDC1 markers Xcr1 and Clec9a, which were reduced in cDC2^FL-Notch^; conversely, cDC1^FL-Notch^ expressed Xcr1 and Clec9a but lacked the cDC2 markers CD11b and CD172a/Sirpα ([Figure S2](#mmc1){ref-type="supplementary-material"}A). All DC^FL-Notch^ had higher levels of CD11c and reduced levels of surface MHC class II; the latter was particularly evident in cDC1s ([Figure 2](#fig2){ref-type="fig"}E). This is consistent with the phenotype of resident cDCs in lymphoid organs, which have higher CD11c and lower MHC class II surface levels than migratory tissue-derived cDCs. Furthermore, cDC2s from FL-Notch cultures showed induction of Esam, a marker of NOTCH2-dependent splenic cDC2s ([Figure 2](#fig2){ref-type="fig"}F). Thus, DL1-NOTCH2 signaling refines the phenotypes of BM-derived cDC subsets and brings them closer to those of the primary resident cDC in lymphoid organs.Figure 2DL1-NOTCH2 Optimizes the Differentiation of cDC1s from the BMTotal murine BM cells were cultured in the presence of FLT3L alone (FL), FLT3L with control OP9 cells (FL+OP9) or FLT3L with OP9 cells expressing Notch ligand DL1 (FL+Notch). OP9 cells were added on day 3, and BM cells were analyzed on day 7 of differentiation.(A) Representative staining plots of differentiated BM cells. The top row shows total live cells with B220^+^ CD11c^lo^ pDCs and B220^−^ CD11c^hi^ cDCs highlighted; the other rows show gated cDCs with CD11b^hi^ cDC2s and/or CD11b^−^ cDC1s highlighted.(B) The expression of CD8α on gated cDCs in BM cultures differentiated as in (A).(C) The subset composition of differentiated BM cells. Shown are fractions of pDCs (of total live cells) and cDC subsets (of gated B220^−^ CD11c^+^ MHC class II^+^ cDCs) and the absolute number of these subsets per 10^5^ initial BM cells. cDC1s were defined either as CD24^+^ or CD8α^+^. Data points represent values from BM cultures of individual mice pooled from 2 experiments; bars represent mean.(D) Representative expression of the indicated surface markers on gated CD24^+^ cDC1s from FL or FL+Notch cultures. The expression of cDC1 markers on cDC2s is included as a control.(E) Representative expression of CD11c and MHC class II on DC subsets from FL or FL+Notch cultures. Subsets were gated, omitting the marker that is shown in each case.(F) Representative expression of Esam on cDC2s from FL or FL+Notch cultures. The expression on cDC1s is included as a control; the dotted line represents negative staining.(G) The effect of NOTCH2 blockade on the expression of CD8α on cDC1s and of Esam on cDC2s. BM cells were differentiated in FL or FL+Notch cultures in the presence of control immunoglobulin G (IgG) or anti-N2; the fluorescence intensity of marker expression in the indicated subsets is shown. Data represent mean ± SD of 5 parallel cultures for anti-N2 and IgG and 9 cultures pooled from 2 experiments for controls.(H) The effect of transcription factor deletion on DC differentiation. BM from control wild-type (WT) mice or mice with DC-specific deletion of *Irf8* (*Irf8* conditional knockout, cKO) or with germline deletion of *Irf8* or *Batf3* were cultured in FL or FL-Notch cultures. Shown is the fraction of the indicated DC subsets among total live cells; data points represent values from individual mice pooled from three (for *Irf8*) or two (for *Batf3*) experiments; bars represent mean.Statistical significance: ^∗∗∗^p \< 0.001, ^∗∗^p \< 0.01, ^∗^p \< 0.05.

The induction of CD8α on cDC1s and of Esam on cDC2s was blocked by anti-N2 Ab ([Figure 2](#fig2){ref-type="fig"}G), confirming NOTCH2 as the relevant receptor. Both DL1- and DL4-expressing OP9 cells were able to induce differentiation of CD8α^+^ cDC1s; however, DL1 induced higher levels of CD8α expression than DL4 ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C). Addition of OP9-DL1 at an earlier (day 1) or later (day 5) time point was less efficient ([Figure S2](#mmc1){ref-type="supplementary-material"}D), suggesting that a durable Notch signal delivered after the initial DC lineage commitment provides optimal DC subset resolution.

As expected, global or DC-specific deletion of *Irf8* spared cDC2s, impaired pDCs, and fully abolished the development of cDC1-like cells in FL cultures ([Figure 2](#fig2){ref-type="fig"}H). On the other hand, deletion of *Batf3* only mildly affected cDC1^FL^ development. cDC1s in FL-Notch cultures showed the same strict dependence on *Irf8* but also a stronger dependence on *Batf3* ([Figure 2](#fig2){ref-type="fig"}H). Furthermore, *Batf3* deletion reduced the expression of CD103 on cDC1s, as described previously ([@bib21]); this effect was particularly prominent in CD103^hi^ cDC1^FL-Notch^ ([Figure S2](#mmc1){ref-type="supplementary-material"}E). Altogether, these results suggest that FL-Notch cultures of primary BM yield cDC1 cells with the appropriate phenotype and genetic requirements.

Notch Signaling Optimizes the Global Expression Profile of *In Vitro*-Derived DCs {#sec2.3}
---------------------------------------------------------------------------------

To further explore the effect of DL1-Notch signaling on *in vitro*-derived DCs, we sorted cDC1s and cDC2s from FL and FL-Notch cultures and interrogated their expression profiles by global mRNA sequencing (RNA-seq). The resulting expression profiles were merged with those of primary splenic cDCs ([@bib22]; [Table S1](#mmc2){ref-type="supplementary-material"}) and compared using multidimensionality scaling (MDS) analysis. As expected, the first dimension separated culture-derived DCs from primary DCs ([Figure S3](#mmc1){ref-type="supplementary-material"}A), whereas the second and third dimensions separated DC subsets ([Figure 3](#fig3){ref-type="fig"}A). By both the second and third dimension, cDC2^FL-Notch^ clustered closer than cDC2^FL^ to primary cDC2 samples, particularly to the NOTCH2-dependent Esam^hi^ subset ([Figure 3](#fig3){ref-type="fig"}A). Moreover, cDC1^FL-Notch^ clustered much closer to primary cDC1 compared with cDC1-like cells from FL cultures ([Figure 3](#fig3){ref-type="fig"}A).Figure 3Notch Signaling Optimizes the Expression Profile of BM-Derived DCsDuplicate samples of sorted DC subsets from FL and FL-Notch cultures of primary BM were analyzed by RNA-seq.(A) Multidimensionality scaling (MDS) analysis of RNA-seq profiles of DC subsets derived from FL cultures (DC1^FL^, DC2^FL^), FL+Notch cultures (DC1^Notch^, DC2^Notch^), and primary splenic DC subsets from WT mice (DC1^WT^, Esam~high~^WT^, and Esam~low~^WT^ DC2s). All samples are plotted on the second and third dimension of MDS.(B) Pairwise comparison of RNA-seq profiles of cDC1 versus cDC2 subsets from the indicated culture conditions. Shown are volcano plots of individual genes, with select subset-specific marker genes highlighted.(C) Pairwise comparison of RNA-seq profiles of the indicated DC subsets generated in FL versus FL-Notch cultures. Shown are volcano plots of individual genes, with select highly differentially expressed genes highlighted.(D) Heatmap of Notch-dependent gene expression in cultured and primary DC subsets. Samples (labeled as in A) were hierarchically clustered by the expression of genes that were downregulated preferentially in *Notch2*-deficient cDC1s, cDC2s, or both cDC1s and cDC2s. Select genes are highlighted; the color scale represents the row *Z* score.

Pairwise comparison between cDC1 and cDC2 for each culture condition showed a greater divergence of the two subsets in FL-Notch cultures ([Figure 3](#fig3){ref-type="fig"}B). In particular, characteristic markers of cDC1 (*Xcr1*, *Clec9a*, *CD36*, and *Tlr11*) and cDC2 (*Itgam* and *Lyz2*) showed greater differential expression. Pairwise comparison between FL and FL-Notch cultures for each subset ([Figure 3](#fig3){ref-type="fig"}C; [Table S2](#mmc3){ref-type="supplementary-material"}) showed that cDC2^FL-Notch^ induced the expression of NOTCH2-dependent genes overexpressed in Esam^hi^ cDC2 ([@bib25], [@bib45]), including canonical Notch targets (*Dtx1* and *Hes1*), characteristic markers (*Esam*), and DC-specific Notch target genes (*Dnase1l3*, *Abcg3*, *Ffar2*, and *Gpr4*). The downregulated genes included markers of Esam^lo^ cDC2 (*Clec12a*) and multiple genes associated with other DC subsets, including pDC (*Siglech*, *Clec10a*, and *CD209d*) and cDC1 (*Xcr1*, *Clec9a*, *CD36*, *Naaa*, and *Tlr11*). In the pairwise comparison of cDC1, the top upregulated gene was *CD8a*; other genes involved in cDC1 function were upregulated (*Il12b* and *Cd1d1*), as were DC-specific NOTCH2 targets (*Dnase1l3*, *Abcg3*, *Ffar2*, and *Gpr4*). Of particular interest was the induction of genes controlling DC migration, including the actin-bundling protein *Fscn1* ([@bib53]) and *Ccr7*, a receptor that guides DC migration from tissues to lymphoid organs ([@bib51]). Conversely, downregulated genes included cDC2 and/or myeloid markers (*Lyz2*, *S100a9*, and *Itgam*) and chemokine receptors that mediate DC migration from blood (*Ccr1*, *Ccr2*, and *Ccr5*). Together with the phenotypic analysis, these data show that Notch signaling optimizes DC subset-specific gene expression and drives their differentiation toward their *in vivo* counterparts.

Finally, we tested whether induced Notch signaling in culture recapitulates the Notch-dependent gene expression program of primary splenic DCs. We compiled genes that were differentially expressed in NOTCH2-deficient splenic cDC1, cDC2, or both subsets ([@bib45]) and analyzed their expression in culture-derived and primary cDC ([Table S3](#mmc4){ref-type="supplementary-material"}). The expression of both NOTCH2-induced genes ([Figure 3](#fig3){ref-type="fig"}D) and NOTCH2-repressed genes ([Figure S3](#mmc1){ref-type="supplementary-material"}B) faithfully clustered cDC1^FL-Notch^ and cDC2^FL-Notch^ with their primary counterparts, whereas cDC1^FL^ and cDC2^FL^ clustered separately from primary cDCs. Both subsets showed upregulation of subset-specific and common Notch target genes, including the abovementioned *Dnase1l3*, *Abcg3*, *Ffar2*, *Gpr4*, *Esam*, and *Dtx1* ([Figure 3](#fig3){ref-type="fig"}D). Notably, cDC1-enriched Notch target genes included *CD8a*, *Fscn1*, and *Ccr7*, suggesting that their induction in cDC1^FL-Notch^ reflects their natural regulation by Notch. Conversely, downregulated genes repressed by Notch included progenitor genes (e.g., *CD34* and *Cx3cr1*), subset-inappropriate genes (e.g., *Tlr4* in cDC1 and *CD36* in cDC2), and chemokine receptor *Ccr2* ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Thus, OP9-DL1 co-cultures facilitate cDC differentiation by recapitulating the physiological Notch-dependent gene expression program of primary cDCs.

Notch Signaling Optimizes Migratory Properties of *In Vitro*-Derived DCs {#sec2.4}
------------------------------------------------------------------------

We examined the distinct functional properties of cDC1s from FL and FL-Notch cultures *in vitro*. Despite the increased baseline expression of *Il12b* ([Figure 3](#fig3){ref-type="fig"}C), cDC1^FL-Notch^ did not show an enhanced interleukin-12 (IL-12) response to the TLR11 ligand profilin (data not shown). Cross-presentation of exogenous protein Ag to CD8^+^ T cells is a hallmark property of cDC1 ([@bib9], [@bib20]). To measure Ag cross-presentation *in vitro*, we pulsed DCs from either culture method with ovalbumin (OVA), washed and incubated them with H-2K^b^-OVA peptide-specific T cell receptor (TCR) transgenic OT-I CD8^+^ T cells, and measured OT-I proliferation by the dilution of the cell tracer dye carboxyfluorescein succinimidyl ester (CFSE). Total DCs and enriched cDC1s from both culture types induced comparably strong OT-I proliferation at a 1:1 DC:T cell ratio (data not shown). At lower DC:T cell ratios (1:5--1:10), total DCs and enriched cDC1s from FL-Notch cultures induced more extensive CFSE dilution in T cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). Thus, Notch signaling is not strictly required for the cross-presenting capacity of cDC1 but facilitates T cell cross-priming under limiting conditions *in vitro*.Figure 4Notch Facilitates CCR7-Dependent Migration of DCsDCs were generated by culturing murine BM cells in the presence of FLT3L alone (FL) or FLT3L with OP9 cells expressing the Notch ligand DL1 (FL+Notch).(A and B) Cross-priming of CD8^+^ T cells *in vitro*. FL or FL-Notch cultures on day 7 were incubated with OVA, and either total cultures or enriched cDC1s were incubated with CFSE-labeled OT-I cells at a 1:10 ratio for 3 days.(A) The levels of CFSE versus the activation marker CD44 in gated CD8^+^ T cells from cultures with the indicated DCs, with the individual peaks of CFSE dilution highlighted. No CFSE dilution was observed in the absence of OVA (data not shown).(B) The fraction of T cells in each peak (mean of 4 parallel cultures ± S.D., representative of 2 experiments).(C) Unsupervised clustering of cultured and primary splenic DCs by the expression of chemokine receptors ([Table S4](#mmc5){ref-type="supplementary-material"}). Shown is the clustering dendrogram with individual replicates of the indicated samples.(D) Heatmap of select chemokine receptor expression in cultured and primary splenic DCs as determined by RNA-seq. The color scale represents the row *Z* score.(E) The expression of CCR7 on the surface of culture-derived DCs. Shown is a representative staining profile and averaged mean fluorescence intensity (MFI) of CCR7 on gated CD11b^+^ cDC2s or CD24^+^ cDC1s. Data represent mean ± range of 2 cultures.(F) DC migration *in vitro* in a transwell assay. Total DCs from FL or FL+Notch cultures were seeded in top chambers with the indicated recombinant chemokine in the bottom chamber and allowed to migrate for 3 hr. Shown is the fraction of each DC subset that migrated into the bottom chamber. Data represent mean ± SD of 4 parallel transwell cultures, representative of 3 experiments.Statistical significance: ^∗^p \< 0.05.

Comparison of DC^FL^ and DC^FL-Notch^ expression profiles identified regulators of cell migration among the most differentially expressed genes ([Figures 3](#fig3){ref-type="fig"}C and 3D). We therefore analyzed the expression of chemokines and their receptors in culture-derived and primary DCs ([Table S4](#mmc5){ref-type="supplementary-material"}). Unsupervised clustering by chemokine expression did not group DC^FL-Notch^ with primary DCs ([Figure S3](#mmc1){ref-type="supplementary-material"}C). Nevertheless, several chemokines were induced in cDC1^FL-Notch^ compared with cDC1^FL^, including *Cxcl9* ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Notably, CXCL9 is preferentially expressed in primary cDC1s ([Figure S3](#mmc1){ref-type="supplementary-material"}D) and plays a major role in cDC1-mediated priming of tumor-specific T cell responses ([@bib8], [@bib49]). The expression of chemokine receptors separated DC^FL^ from other samples but clustered DC^FL-Notch^ with their respective splenic DC counterparts ([Figure 4](#fig4){ref-type="fig"}C). Furthermore, cDC1^FL-Notch^ showed a profound downregulation of *Ccr1*, *Ccr2*, and *Ccr5* and induction of *Ccr7*, aligning the expression of these receptors with primary cDC1 ([Figure 4](#fig4){ref-type="fig"}D). The induction of *Ccr7* in cDC1^FL-Notch^ was particularly notable given its very low levels in cDC1^FL^. Cell surface staining confirmed the induction of CCR7 expression on DC^FL-Notch^ ([Figure 4](#fig4){ref-type="fig"}E). Accordingly, transwell migration assays showed that all DC^FL^ preferentially migrated toward the CCR2 ligand CCL2, with lower migration toward the CCR1 and CCR5 ligand CCL5 and CCR7 ligand CCL19 ([Figure 4](#fig4){ref-type="fig"}F). In contrast, DC^FL-Notch^ failed to migrate toward CCL2 or CCL5, but showed increased migration toward CCL19, with the difference being particularly notable in the cDC1 subset ([Figure 4](#fig4){ref-type="fig"}F). These data suggest that Notch signaling induces a more physiological pattern of chemokine receptor expression and migration in cultured DCs, specifically favoring CCR7-dependent over CCR2- and CCR5-dependent migration.

Notch Signaling Facilitates cDC1-Mediated T Cell Cross-Priming and Antitumor Vaccination {#sec2.5}
----------------------------------------------------------------------------------------

Given the optimized cross-presenting and migratory properties of DC^FL-Notch^ *in vitro*, we tested the ability of these cells to cross-prime T cell responses *in vivo*. DCs from FL or FL-Notch cultures were pulsed with OVA, and either total DCs or enriched CD24^+^ cDC1s ([Figure S4](#mmc1){ref-type="supplementary-material"}A) were transferred into wild-type syngeneic H-2K^b^ recipients. One week later, OVA-specific endogenous CD8^+^ T cells were detected with an H-2K^b^-OVA peptide (SIINFEKL) tetramer. We found that up to 10^6^ cells/animal of DC^FL^ failed to elicit OVA-specific T cells in the spleen ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and in the peripheral blood ([Figures 5](#fig5){ref-type="fig"}A and 5B). In contrast, DC^FL-Notch^ induced robust T cell responses even at lower doses (0.25--0.5 × 10^6^ cells/animal) ([Figure S4](#mmc1){ref-type="supplementary-material"}B; [Figures 5](#fig5){ref-type="fig"}A and 5B). Furthermore, a major improvement in T cell priming was also observed when the same experiments were done with enriched cDC1^FL-Notch^ ([Figures 5](#fig5){ref-type="fig"}A and 5C). The comparison of total DCs to cDC1s in these experiments was confounded by the cDC1 isolation procedure and by potential saturation of the T cell response. Nevertheless, it is notable that neither total DC^FL^ nor enriched cDC1^FL^ could cross-prime at any dose, whereas total DC^FL-Notch^ and cDC1^FL-Notch^ were comparably efficient.Figure 5Notch Facilitates cDC1-Mediated T Cell Cross-Priming *In Vivo*DCs from FL or FL+Notch cultures of primary murine BM were incubated with OVA, and total DCs or enriched cDC1s were injected i.v. into naive WT syngeneic recipient mice. The priming of endogenous OVA peptide-specific CD8^+^ T cells was determined 7 days later by staining of PB leukocytes with H-2K^b^-OVA peptide tetramer.(A) Representative staining profiles of gated CD44^+^ TCRβ^+^-activated T cells in the PB, with the CD8^+^ tetramer^+^ cells highlighted.(B) The fraction of OVA-specific T cells among total CD44^+^ TCRβ^+^ CD8^+^ cells after vaccination with the indicated numbers of total DCs. Mice that received no injection (control) or a mock PBS injection are shown as well. Data points represent values from individual mice pooled from 2 experiments; bars represent mean.(C) The fraction of OVA-specific T cells after vaccination with 3 × 10^5^ enriched cDC1s. Data points represent values from individual mice pooled from 3 experiments; bars represent mean.(D) Kaplan-Meier survival plot of animals that were vaccinated with OVA-pulsed total DCs and subsequently challenged with the OVA-expressing melanoma cell line.Statistical significance: ^∗∗∗∗^p \< 0.0001, ^∗∗∗^p \< 0.001.

To test the consequences of differential T cell priming, recipient mice were challenged with the OVA-expressing syngeneic melanoma cell line B16 (B16-OVA). After intravenous (i.v.) retroorbital administration of 2.5 × 10^5^ B16-OVA cells, all untreated mice became moribund with respiratory distress within ∼2 weeks and had to be sacrificed ([Figure 5](#fig5){ref-type="fig"}D). Histological analysis of the lungs showed disseminated infiltration of the alveolar space by B16 cells, likely causing respiratory failure ([Figure S4](#mmc1){ref-type="supplementary-material"}C). A similar mortality was observed in all mice vaccinated with OVA-pulsed total DC^FL^ ([Figure 5](#fig5){ref-type="fig"}D). In contrast, vaccination with OVA-pulsed total DC^FL-Notch^ conferred near-complete protection against B16-OVA challenge ([Figure 5](#fig5){ref-type="fig"}D). The single DC^FL-Notch^ recipient that succumbed to the tumor harbored a low fraction (\<0.2%) of OVA-specific T cells, confirming the dependence of protection on T cell priming. We also performed these experiments injecting B16-OVA cells i.v. through the tail vein; this route of administration yielded the characteristic focal growth of melanoma cells in the lungs. Again, vaccination with OVA-pulsed DC^FL^ had no effect, whereas vaccination with DC^FL-Notch^ strongly reduced the growth of melanoma foci ([Figure S4](#mmc1){ref-type="supplementary-material"}D). We conclude that FL-Notch culture generates cDC1s with a superior capacity for T cell cross-priming and antitumor vaccination.

Notch Signaling Facilitates Development of cDC1s from Human Hematopoietic Progenitors {#sec2.6}
-------------------------------------------------------------------------------------

The potential therapeutic properties of cDC1s, but their rarity *in vivo*, led us to explore *in vitro* differentiation approaches in humans. Culture of BM CD34^+^ progenitors in liquid medium supplemented with the cytokines FLT3L, stem cell factor (SCF), and GM-CSF (FSGM) generated only CD14^+^ and CD1c^+^ monocyte-like or cDC2-like cells ([Figure 6](#fig6){ref-type="fig"}A). Addition of an OP9 feeder layer supported the simultaneous generation of all three DC subsets with a low yield of 0.4 cDC1s per input CD34^+^ progenitor ([Figure 6](#fig6){ref-type="fig"}B). Addition of a Notch signal by co-culture with OP9-DL1 cells resulted in selective expansion of cDC1s, increasing the cDC1 output ∼11-fold (4.4 cDC1s per input progenitor) on day 14 of culture. A lower expansion of cDC1s (2.8 cDC1s/progenitor) was seen on exposure of progenitors to OP9-DL4 under similar culture conditions ([Figures 6](#fig6){ref-type="fig"}A and 6B). cDC1 expansion was dependent on a continuous Notch signal because withholding or withdrawing Notch ligand for the first or last 7 days, respectively, decreased the effect ([Figure S5](#mmc1){ref-type="supplementary-material"}A).Figure 6Notch Facilitates cDC1 Development from Human BM Progenitors(A and B) Sorted CD34^+^ stem and progenitor cells purified from human BM were cultured for 2 weeks in the presence of a FLT3L-containing cytokine mix (FSGM) or on monolayers of control OP9, OP9-DL1, or OP9-DL4 cells.(A) Representative staining profiles highlighting the indicated DC subsets in the resulting cultures; primary DCs from the PB are included for comparison. Numbers represent the percentage of gated cells.(B) Absolute numbers of DC subsets generated in a 0.2-mL culture standardized to 3,000 CD34^+^ progenitor cell input. Data points represent values in BM cultures from different donors (n = 8 for OP9, 7 for OP9-DL1, and 2 for OP9-DL4); bars represent mean with SEM. The indicated p values were derived by unpaired two-tailed t test. The data represent the absolute number of DC subsets per input progenitor cell.(C) Comparison of expression profiles of culture-derived and primary DC subsets based on the Nanostring nCounter analysis. Shown is the principal-component analysis of the indicated triplicate samples after removal of the "culture signature" derived by pairwise comparison of all culture-generated versus *ex vivo* cells.(D and E) Representative staining profiles (D) and cell yields (E) of the cultures of BM from the two patients with biallelic *IRF8* mutations (IRF8^108E/108E^ or IRF8^83C/291Q^). The experiments were done as in (A) and (B).

Culture-generated cDC1s expressed the human cDC1-specific markers CD141 and CLEC9A at levels comparable with or higher than *ex vivo* blood cDC1s ([Figure S5](#mmc1){ref-type="supplementary-material"}B). However, they expressed low levels of CD11c and high levels of CD1c, differing from peripheral blood (PB) cDC1s but resembling the phenotype of peripheral tissue cDC1s ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Next we performed a gene expression analysis on the NanoString nCounter platform running the Human Immunology v2 panel (594 genes) with the addition of 30 DC-specific genes ([Table S5](#mmc6){ref-type="supplementary-material"}). Expression profiles were compared after removal of the genes with low expression levels and of the genes that were differentially expressed between all culture and all *ex vivo* subsets (the cell culture signature). By subsequent principal-component analysis based on 339 genes, the first component separated pDCs from cDCs and the second cDC1s from cDC2s ([Figure 6](#fig6){ref-type="fig"}C). Notably, OP9-DL1-differentiated cDC1s grouped closely with OP9-derived cDC1s and with primary cDC1s from the PB. Accordingly, genes encoding subset-specific transcription factors, surface markers, and TLRs were expressed faithfully, including *CLEC9A*, *XCR1*, *TLR3*, *IRF8*, and *BATF3* in cDC1s ([Figure S5](#mmc1){ref-type="supplementary-material"}C). The expression of chemokine receptors was similarly segregated by subset ([Figure S5](#mmc1){ref-type="supplementary-material"}D), although a higher expression of CCR7 in OP9-derived cDC1s and cDC2s was noted. In contrast, the expression of chemokines segregated OP9-derived cDC1s and cDC2s, which showed higher levels of *CXCL10*, *CXCL12*, and *CCL22* than either DL1-derived DCs or primary DCs ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Thus, unlike in the mouse system, OP9-DL1 does not appear to affect the overall expression profile or the expression of migration regulators in cDC1s. Nevertheless, we conclude that DL1-induced Notch signaling greatly increases the number of differentiated cDC1s with the appropriate expression profile.

Biallelic *IRF8* mutation in human abrogates pDC, cDC1, and cDC2 development *in vivo* ([@bib4], [@bib17]). To interrogate the IRF8 requirement for *in vitro* Notch-induced cDC1 expansion, IRF8^108E/108E^ and IRF8^83C/291Q^ CD34^+^ progenitors were co-cultured with either OP9 or OP9-DL1. cDC1s and pDCs failed to emerge under either condition, whereas some cDC2 generation was observed ([Figures 6](#fig6){ref-type="fig"}D and 6E). Thus, Notch signaling from DL1 specifically facilitates the development of human cDC1s with the appropriate phenotype, expression profile, and genetic requirements.

Notch-Driven Differentiation Results in Functional Human cDC1s {#sec2.7}
--------------------------------------------------------------

To interrogate the functional capacity of *in vitro*-generated DCs, we examined cytokine production in response to TLR agonists. PB mononuclear cells or *in vitro*-derived DCs were exposed to a cocktail of TLR agonists (CL075, CpG, lipopolysaccharide \[LPS\], and poly-I:C), and subset-specific cytokine production was assessed by intracellular flow cytometry ([Figures 7](#fig7){ref-type="fig"}A and 7B). Tumor necrosis factor (TNF) production by cDC1s was significantly increased in OP9-DL1-derived compared with OP9-derived cells and comparable with blood cDC1s. No significant increase in IL-12 production was observed in cDC1s or cDC2s generated *in vitro*, but a decrease in both TNF and interferon α (IFN-α) was observed in DL1-derived pDCs ([Figure 7](#fig7){ref-type="fig"}B).Figure 7Notch-Driven Differentiation Yields Functional Human cDC1sDCs generated from CD34^+^ progenitors in cultures with OP9 or OP9-DL1 were analyzed in parallel to primary DCs from PB.(A and B) Cytokine production by DCs stimulated for 14 hr with a cocktail of TLR agonists (poly-I:C, LPS, CL075, and CpG).(A) Representative flow cytometric analysis of intracellular cytokine production (TNF, IL-12, and IFN-α) in the indicated gated DC subsets from OP9-DL1 cultures. Grey contours represent unstimulated cells; numbers represent the cytokine-positive fraction.(B) Proportion of cytokine-positive cDC1s (purple), cDC2s (red), or pDCs (blue) generated from CD34^+^ progenitors in culture with OP9 (n = 4) or OP9-DL1 (n = 3) cells compared with PB primary (n = 7) cells following TLR stimulation. Circles, histograms, and bars represent individual experiments, mean, and SEM, respectively; p values are indicated.(C and D) T cell stimulation by DCs cultured with sorted allogeneic blood CD3^+^ T cells.(C) Representative flow cytometric analysis of T cell proliferation in response to culture with DCs. The data show output of a T cell and cDC1 (generated with OP9-DL1) culture. CD11c^+^ CD141^+^ cDC1s could be identified (purple gate) and gated out. CD3^+^ T cells were subdivided by CD8 and CD4 expression. Cell division was indicated by CFSE dilution (turquoise gate).(D) Proportion of CD4^+^ or CD8^+^ T cells that underwent division (CFSE dilution) in culture with cDC1 (purple) or cDC2 (red) isolated from PB or generated in culture with OP9 or OP9-DL1 (DL1) cells. T cells cultured alone or with beads coated with anti-CD3 plus anti-CD28 were used as negative (Neg) and positive (Pos) controls, respectively. Responses to blood DCs were generated from 2--3 DC donors and 3 T cell donors (2--6 independent experiments). Responses to cultured DCs were generated from 2 BM donors combined with 3 T cell donors (4--6 independent experiments). Each circle represents an independent experiment (mean of 1--3 technical replicates). Histograms and bars represent mean and SEM, respectively. The p values were derived from unpaired two-tailed Student's t test.

Culture-derived cDC1s showed appropriate migration in a transwell assay toward the XCR1 ligand XCL1 as well as weaker migration toward CCR2, CCR5, and CCR7 ligands; no major differences between OP9- and OP9-DL1-derived DCs were noted (data not shown). To assess their T cell-stimulatory capacity, cDC1s and cDC2s from the PB or from *in vitro* cultures were sorted and co-cultured with allogeneic T cells. The proportion of CD4^+^ or CD8^+^ T cells that underwent division was determined by CFSE dilution ([Figure 7](#fig7){ref-type="fig"}C). It should be noted that no differences were expected between CD4^+^ and CD8^+^ T cells in this assay, which measures direct T cell activation rather than cross-priming. cDC1s generated on OP9-DL1 stimulated proliferation in a significantly greater proportion of both CD4^+^ and CD8^+^ T cells compared with those generated on OP9; this effect was not observed in cDC2s ([Figure 7](#fig7){ref-type="fig"}D). We conclude that Notch signaling induces the development of functionally intact cDC1s, which show a significant improvement in their *in vitro* T cell priming capacity. Together with the drastic increase of cDC1 yield, these data underscore the improvement of cDC1 generation in Notch-driven cultures.

Discussion {#sec3}
==========

We describe an *in vitro* method of DC generation based on the combination of two cell-extrinsic signals, FLT3L and Notch. FLT3L is the key cytokine for the DC lineage and alone is sufficient to drive DC development and subset specification from murine hematopoietic progenitors. Murine FLT3L-derived cDCs harbor a population of IRF8-dependent cDC1-like cells (cDC1^FL^) that manifest functional hallmarks of cDC1s, such as IL-12 production and T cell cross-priming *in vitro* ([@bib34]). However, these cells have an abnormal CD11b^+^ CD8α^−^ Dec205^−^ CD103^−^ phenotype, fail to migrate toward CCR7, and are shown here to have a poor capacity for T cell cross-priming *in vivo*. A combination of FLT3L with the cytokine GM-CSF in a two-step culture selectively expands cDC1-like cells and confers CD103 expression, yielding so-called iCD103-DCs ([@bib29]). However, iCD103-DCs have the same aberrant CD11b^+^ CD8α^−^ Dec205^low^ phenotype and lack CCR7 expression unless stimulated with TLR ligands. Moreover, their expression profile and functional properties were never directly compared with those of cDC1^FL^, and their T cell priming capacity *in vivo* was tested only after TLR-induced activation ([@bib29]). Thus, apart from the expected induction of CD103 ([@bib54]), GM-CSF does not appear to improve the quality of FLT3L-derived cDCs. Conversely, stromal cells expressing the Notch ligand DL1 were reported to improve DC differentiation in GM-CSF cultures, but these do not generate any cDC1 output ([@bib7]).

Here, we show that the introduction of the Notch ligand DL1 into FLT3L-driven culture using the OP9-DL1 stromal cell line ([@bib46]) yields the two main cDC subsets, including *bona fide* CD11b^−^ CD8α^+^ Dec205^+^ CD103^+^ cDC1s. Indeed, cDC1s and cDC2s became more distinct by key surface markers and by global expression profile, at the same time better resembling their primary counterparts in the spleen. Notably, cDC2s showed higher similarity to the Esam^hi^ subset of splenic cDC2s, which manifest a superior ability to prime T cells ([@bib25]). Most importantly, the cDC1 subset manifested the appropriate surface phenotype and expression profile and an improved ability to cross-prime CD8^+^ T cell responses. The latter underscores a dramatic improvement in the quality of resulting cDC1s, even as the fraction and numbers of cDC1s were not increased. Indeed, Notch-derived cDC1s dramatically outperformed conventional cDC1-like cells in T cell priming *in vivo*, even at much lower numbers. Moreover, the potential limitation of cell numbers can be overcome by our system's application to immortalized DC progenitors, which can be scaled up indefinitely.

The improved functionality of Notch-derived cDC1s does not appear to reflect an effect on Ag cross-presentation capacity per se because cDC1-like cells from FL cultures could cross-present *in vitro*, as described previously ([@bib34]). Instead, it is likely due to an enhanced capacity to recruit T cells (e.g., through the elevated expression of CXCL9) and/or to migrate toward appropriate locations in lymphoid organs. These functions are less important when DCs and T cells interact in the artificial context of *in vitro* cultures (except at lower DC:T cell ratios) but are critical for T cell priming *in vivo*. FL-Notch co-cultures switched the chemokine receptor expression pattern of the resulting DCs from CCR1, CCR2, and CCR5 toward CCR7, recapitulating that of DCs in lymphoid organs. This switch facilitated the migration toward CCR7 ligands, the process that guides DCs into T cell zones and is essential for T cell priming *in vivo* ([@bib51]). Collectively, Notch signaling increases the similarity of *in vitro*-generated DCs to their primary counterparts in the lymphoid organs, optimizing the functional properties of cDC1s.

Notch signaling is important for the differentiation of cDC2s in the spleen and intestine; indeed, these cells express Notch target genes such as *Hes1* and *Dtx1*, are located in DL1-expressing splenic niches, and depend on NOTCH2 and the canonical RBPJ-mediated signaling downstream of it ([@bib6], [@bib25]). In contrast, cDC1s express few or no Notch target genes and are unaffected by DC-specific loss of *Rbpj* ([@bib6]); however, *Notch2* deletion impairs their phenotype and expression profile ([@bib25], [@bib45]). Consistent with the latter observation, our results identify the DL1-NOTCH2 axis as a signal that is missing in conventional FLT3L cultures and whose induction can drive differentiation into authentic functional cDC1s. To reconcile these data, we propose that DL1-NOTCH2 signaling is an important extrinsic signal for cDCs in the spleen (and possibly other lymphoid organs) that acts on committed cDC progenitors to facilitate cDC1 and cDC2 subset specification and terminal differentiation. This signal then stays "on" in Esam^hi^ cDC2, which remain in contact with DL1-expressing stroma and are fully dependent on DL1 signaling through NOTCH2-RBPJ for their survival. In contrast, the DL1-NOTCH2 signal may be turned "off" as cDC1s migrate throughout the spleen and lose Notch target gene expression and NOTCH2-RBPJ dependence. Overall, our studies emphasize the critical role of Notch signaling in the functional differentiation of both cDC subsets and demonstrate its utility to facilitate cDC generation *in vitro*.

FLT3L alone appears to be insufficient to drive DC development from human hematopoietic progenitors and has to be supplemented with other cytokines ([@bib3], [@bib37], [@bib38]) or stromal cell lines, including MS5 alone ([@bib23]) or a mixture of MS5 and OP9 ([@bib24]). These conditions can generate mature CD141^+^ cDC1s with the appropriate phenotype, expression profile, and *in vitro* functionality. However, the fraction and absolute numbers of the resulting cDC1s are low in all cases, hampering their detailed functional characterization and practical use. This situation appears to be different from that in the mouse, where FLT3L alone can drive the development of abundant but not fully mature cDC1-like cells. It was recently reported that co-culture of human thymic progenitors with OP9-DL1 blocked the emergence of DC progenitors but increased the yield of cDCs from the latter ([@bib28]); neither the net effect on DC development nor the resulting DC phenotypes were investigated. We report that, although co-culture of human BM progenitors with OP9 generates all DC subsets, addition of the Notch ligand DL1 resulted in a more than 10-fold increase in cDC1 output per progenitor cell. The resulting cDC1s aligned closely with their *ex vivo* counterparts by gene expression analysis, were strictly IRF8-dependent, and showed increased T cell-stimulatory capacity. In contrast to mouse BM cultures, DL1 was required continuously from the beginning of the culture; furthermore, unlike in the mouse system, no major effects of DL1 on the phenotype, expression profile, or migration of the resulting cDC1s were noted. This may reflect different comparators for OP9-DL1 cultures ("FLT3L only" in the mouse and "FLT3L with other cytokines and OP9" in the human); differences in the effect of murine OP9 cells and their products (cytokines, adhesion molecules) on murine versus human cells; and/or biological differences between the two species. In each case, however, Notch signaling appeared to solve a major hurdle to cDC1 differentiation; i.e., it improve the suboptimal expression profile and functionality in the mouse and increase low numbers in humans. Collectively, these results emphasize the conserved positive effect of Notch signaling on *in vitro* cDC1 differentiation.

The long-standing idea of DC-based vaccination against tumors ([@bib36]) is now being actively pursued in human patient studies, especially in combination with other immunotherapies ([@bib14]). cDC1s appear to play a particularly important role in antitumor responses through their efficient cross-priming of tumor-specific cytotoxic T cells ([@bib5], [@bib43], [@bib44], [@bib49]). The utility of cDC1s for antitumor vaccination is further illustrated by our results in the mouse, in which Notch-derived cDC1s protected against tumor challenge whereas larger numbers of total FL-derived DCs did not. The utility of human cDC1s for antitumor vaccination so far has been severely limited by their rarity *in vivo* and low yield *in vitro*. Our system overcomes this hurdle by increasing the output of human cDC1s by an order of magnitude, facilitating their potential use for vaccination. Notably, Notch-derived cDC1s are functional *in vivo* without prior TLR-induced activation, an important advantage for translational applications. Furthermore, the activation-independent functionality of Notch-derived DCs supports their potential application for tolerogenic DC vaccination; e.g., against autoimmune diseases. Collectively, the methods of *in vitro* DC generation described here should facilitate mechanistic and translational studies focused on the therapeutic potential of DCs.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rat anti-mouse CD45 (clone 30-F11)BD BiosciencesCat\# 550994Rat anti-mouse CD205 (clone NLDC-145)BioLegendCat\# 138207Rat anti-mouse CD317 (Bst2) (clone 927)BioLegendCat\# 127012Rat anti-mouse CD205 (clone NLDC-145)BioLegendCat\# 138209, 138205Rat anti-mouse/human CD45R/B220 (clone RA3-6B2)BioLegendCat\# 103232Rat anti-mouse CD127 (clone A7R34)eBioscienceCat\# 11-1271-81Armenian hamster anti-mouse CD11c (clone N418)eBioscienceCat\# 11-0114-82, 13-0114-85Rat anti-mouse CD4 (clone GK1.5)eBioscienceCat\# 11-0041-82Rat anti-mouse CD135 (FLT3) (clone A2F10)eBioscienceCat\# 46-1351-80Rat anti-mouse CD8a (clone 53-6.7)eBioscienceCat\# 45-0081-82, 17-0081-83Rat anti-mouse/human CD44 (clone IM7)eBioscienceCat\# 17-0441-83Rat anti-mouse CD25 (clone PC61.5)eBioscienceCat\# 12-0251-82Rat anti-mouse CD11b (clone M1/70)eBioscienceCat\# 47-0112-82, 25-0112-81Rat anti-mouse CD117 (c-Kit) (clone 2B8)eBioscienceCat\# 47-1171-80Armenian hamster anti-mouse TCR beta (clone H57-597)eBioscienceCat\# 47-5961-82Syrian hamster anti-mouse CD3e (clone eBio500A2)eBioscienceCat\# 48-0033-82Rat anti-mouse CD24 (clone M1/69)eBioscienceCat\# 12-0242-81Rat anti-mouse ESAM (clone 1G8)eBioscienceCat\# 12-5852-81Rat anti-mouse CD115 (c-fms) (clone AFS98)eBioscienceCat\# 12-1152-81Armenian hamster anti-mouse CD103 (clone 2E7)eBioscienceCat\# 12-1031-81Rat anti-mouse/human CD45R (B220) (clone RA3-6B2)eBioscienceCat\# 25-0452-82Rat anti-mouse CD4 (clone RM4-5)eBioscienceCat\# 25-0042-81Rat anti-mouse MHC Class II (I-A/I-E) (clone M5/114.15.2)eBioscienceCat\# 56-5321-82Mouse anti-mouse NK1.1 (clone PK136)eBioscienceCat\# 48-5941-80Rat anti-mouse TER-119 (clone TER-119)eBioscienceCat\# 48-5921-82Rat anti-mouse Ly-6G (Gr-1) (clone RB6-8C5)eBioscienceCat\# 48-5931-82Rat anti-mouse CCR7 (clone 4B12)eBioscienceCat\# 12-1971-82Anti-mouse Clec9a (clone 42D2)eBioscienceCat\# 12-5975-80Anti-mouse Xcr1 (clone ZET)BioLegendCat\# 148207Anti-mouse CD172a (clone P84)BD BiosciencesCat\# 560107Synthetic human anti-mouse/human NOTCH2 negative regulatory region (NRR)([@bib52])N/AMouse anti-human CD11c (AF700/BV605/BV711 conjugate, clone B-ly6, 3/5/5 μl/50 μl sample)BD/BD/BiolegendCat\# 561352, 563929, 301630Mouse anti-human CD123 (BV421/BUV395 conjugate, clone 6H6/7G3, 3/5 μl/50 μl sample)Biolegend/BDCat\# 306018, 564195Mouse anti-human CD14 (BV650 conjugate, clone M5E2, 4 μl/50 μl sample)BiolegendCat\# 301835Mouse anti-human CD141 (BV510/APC conjugate, clone 1A4/AD5-14H12, 3/5 μl/50 μl sample)BD/MiltenyiCat\# 563298, 130-090-907Mouse anti-human CD15 (BV605 conjugate, clone W6D3, 3 μl/50 μl sample)BDCat\# 562980Mouse anti-human CD16 (FITC/AF700 conjugate, clone 3G8, 3/1 μl/50 μl sample)BD/BiolegendCat\# 335035, 302026Mouse anti-human CD19 (FITC/AF700 conjugate, clone 4G7/HIB19, 3/1 μl/50 μl sample)BD/BiolegendCat\# 345776, 302226Mouse anti-human CD1c (PE-Cy7/PerCP-Cy5.5 conjugate, clone L161, 3/5 μl/50 μl sample)BiolegendCat\# 331516, 331513Mouse anti-human CD20 (FITC/AF700 conjugate, clone L27/2H7, 3/1 μl/50 μl sample)BD/BiolegendCat\# 345792, 302322Mouse anti-human CD3 (FITC/AF700 conjugate, clone SK7 (Leu-4), 3/5 μl/50 μl sample)BD/BiolegendCat\# 345763, 344822Mouse anti-human CD303 (BDCA-2) (APC/BV605 conjugate, clone 201A, 3/5 μl/50 μl sample)BiolegendCat\# 354206, 354224Mouse anti-human CD304 (APC/BV605 conjugate, clone 12C2/U21-1283, 3/5 μl/50 μl sample)Biolegend/BDCat\# 354506, 743130Mouse anti-human CD34 (FITC conjugate, clone 8G12, 3 μl/50 μl sample)BDCat\# 345801Mouse anti-human CD4 (BV421 conjugate, clone RPA-T4, 5 μl/50 μl sample)BiolegendCat\# 300531Mouse anti-human CD45 (APC-Cy7 conjugate, clone 2D1, 3 μl/50 μl sample)BDCat\# 557833Mouse anti-human CD56 (FITC conjugate, clone NCAM16.2, 3 μl/50 μl sample)BDCat\# 345811Mouse anti-human CD8 (APC-Cy7 conjugate, clone SK1, 5 μl/50 μl sample)BDCat\# 557834Mouse anti-human CLEC9A (CD370, DNGR1) (PE conjugate, clone 8F9, 3 μl/50 μl sample)BiolegendCat\# 353804Mouse anti-human HLA-DR (PerCP-Cy5.5/BV785/V500 conjugate, clone L243/L243/G46-6, 3/5/5 μl/50 μl sample)BD/Biolegend/BDCat\# 339216, 307642, 561224Mouse anti-human IL-12p40/p70 (BV421 conjugate, clone C8.6, 5 μl/50 μl sample)BDCat\# 565023Mouse anti-human IFN-a (PE conjugate, clone LT27:295, 10 μl/50 μl sample)MilteyniCat\# 130-092-601Mouse anti-human TNF-a (APC-Cy7 conjugate, clone Mab11, 5 μl/50 μl sample)BiolegendCat\# 502944**Chemicals, Peptides, and Recombinant Proteins**DAPISigma-AldrichCat\# D8417Permeabilization buffereBioscienceCat\# 00-8333-56Paraformaldehyde (PFA) 4% in PBSAffymetrixCat\# 19943 1LTMitomycin C from *Streptomyces caespitosus*Sigma-AldrichCat\# T5648CFSEInvitrogenCat\# C34554Brefeldin ASigma-AldrichCat\# B7651Streptavidin PerCP-Cyanine5.5eBioscienceCat\# 45-4317-82Streptavidin APCeBioscienceCat\# 17-4317-82Fixable Viability Dye eFluor 506eBioscienceCat\# 65-0866-14iTAg Tetramer/PE - H-2 Kb OVA (SIINFEKL)MBL InternationalCat\# TB-5001-1Collagenase DSigma-AldrichCat\# COLLD-ROChromPure mouse IgGJackson LaboratoriesCar\# 015-000-003Deoxyribonuclease I (DNase I) from bovine pancreasSigma-AldrichCat\# D5025Ovalbumin from chicken egg white, endotoxin-free (OVA)InvivoGenCat\# vac-ovaStreptavidin microbeadsMiltenyi BiotecCat\# 130-048-101DNase IQIAGENCat\# 79254Recombinant murine SLC (CCL21)PeprotechCat\# 250-13Recombinant murine RANTES (CCL5)PeprotechCat\# 250-07Recombinant murine MCP-1 (CCL2)PeprotechCat\# 250-10Recombinant murine MIP-3β (CCL19)PeprotechCat\# 250-27BFCS, charcoal strippedGIBCOCat\# 12676-029TRIzol LS ReagentInvitrogenCat\# 10296028**Critical Commercial Assays**ARCTURUS PicoPure RNA Isolation KitApplied BiosystemsCat\# KIT0204**Deposited Data**RNA-seq analysis of cultured dendritic cellsThis paperGEO: [GSE110577](ncbi-geo:GSE110577){#intref0010}RNA-seq analysis of primary splenic dendritic cells([@bib22])GEO: [GSE76132](ncbi-geo:GSE76132){#intref0015}Microarray analysis of *Notch2*-deficient dendritic cells([@bib45])GEO: [GSE45681](ncbi-geo:GSE45681){#intref0020}**Experimental Models: Cell Lines**Mouse: OP9-GFP([@bib32])N/AMouse: OP9-DL1([@bib32])N/AMouse: OP9-DL4([@bib32])N/AMouse: B16-OVA([@bib11])N/AMouse: B16-FLT3L([@bib27])N/AMouse: HoxB8-FL([@bib42])N/A**Experimental Models: Organisms/Strains**Mouse: C57BL/6The Jackson LaboratoryStock \#000664Mouse: Rag2/OT-ITaconic2334Mouse: *Irf8*^*−/−*^ :B6(Cg)-*Irf8*^*tm1.2Hm*^/J([@bib35])N/AMouse: *Irf8*^*flox*^ : B6(Cg)-*Irf8*^*tm1.1Hm*^/J([@bib13])N/AMouse: *Itgax-Cre*: B6.Cg-Tg(Itgax-cre)1-1Reiz/J([@bib6])N/AMouse: *Batf3*^*−/−*^: B6.129S(C)-*Batf3*^*tm1Kmm*^/J([@bib20])N/A**Software and Algorithms**FlowJo v9.9.5 and v10.1FlowJo, LLC<https://www.flowjo.com/>Prism 7GraphPad<https://www.graphpad.com/>DESeq2 (v3.0)([@bib26])<http://bioconductor.org/packages/release/bioc/html/DESeq2.html>R (v.3.3.2).N/A<https://www.r-project.org/>STAR anligner (v2.5.0c)([@bib10])<https://github.com/alexdobin/STAR>Picard tools (v.1.126)<http://broadinstitute.github.io/picard/>HTSeq (v0.6.0)([@bib2])<https://github.com/simon-anders/htseq>BEDTools (v2.17.0)([@bib40])<https://github.com/arq5x/bedtools2>nSolver (advanced analysis module v.1.1.4)Nanostring<https://www.nanostring.com/products/analysis-software/nsolver>

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Boris Reizis (<Boris.Reizis@nyumc.org>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Human studies {#sec4.3.1}

The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from participants prior to recruitment. The study was approved by NRES Committee North East-Newcastle and North Tyneside (08/H0906/72, 14/NE/1212 and 14/NE/1136). Peripheral blood or bone marrow was obtained from healthy volunteers or from the previously described patients with biallelic *IRF8* mutations ([@bib4], [@bib17]).

### Animals {#sec4.3.2}

All animal studies were performed according to the investigator's protocol approved by the Institutional Animal Care and Use Committees of New York University School of Medicine and of Columbia University Medical Center. Wild-type C57BL/6 mice (Jackson Laboratories) and Rag2-deficient OT-I TCR transgenic mice (Rag2/OT-I, Taconic) were maintained by intercrossing in the animal facility at New York University School of Medicine. Mice deficient for *Batf3* ([@bib20]) or Irf8 ([@bib35]), mice with a conditional LoxP-flanked allele of *Irf8* (*Irf8*^flox^) ([@bib13]) and the *Itgax*-Cre deleter strain ([@bib6]) have been described previously and were on pure C57BL/6 background. *Irf8*^flox^ and *Itgax*-Cre mice were intercrossed to obtain *Irf8*^flox/flox^ *Itgax*-Cre^+^ mice with a specific deletion of Irf8 in CD11c^+^ cells. Mice were group-housed in individually ventilated cages and maintained under specific pathogen-free conditions. Male and female mice were used between 8 and 16 weeks of age. No obvious difference between sexes was observed within the parameters analyzed for our experiments.

### Cell lines {#sec4.3.3}

FLT3L-secreting ([@bib27]) and OVA-expressing ([@bib11]) clones of the C57BL/6-derived B16 melanoma cell line (B16-FLT3L and B16-OVA, respectively) were cultured in DMEM medium supplemented with 10% fetal calf serum (FCS), 1% L-glutamine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin (full DMEM) at 37°C in a humidified atmosphere at 5% CO~2~. The murine progenitor Hoxb8-FL cell line ([@bib42]) was cultured in RPMI medium supplemented with 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin, 10% supernatant from cultured B16-FLT3L cell line and 1 μm β-estradiol at 37°C in a humidified atmosphere at 5% CO~2~. For differentiation, Hoxb8-FL cells were cultured in the same medium without estradiol and with charcoal-stripped FCS to ensure the absence of estradiol. OP9 cell lines transduced with retroviruses encoding green fluorescent protein (GFP) or Notch ligands DL1 or DL4 ([@bib32], [@bib46]) were cultured in MEM-α medium supplemented with 20% FCS and 1% penicillin/streptomycin (OP9 medium) at 37°C in a humidified atmosphere at 5% CO~2.~ Prior to use in co-cultures, OP9 cells were treated with mitomycin C at 10 μg/mL for 2 hr, harvested, washed three times in PBS and resuspended in OP9 medium. For co-culture with human cells, OP9 were maintained in MEM-α supplemented with 10% FCS and 1% penicillin/streptomycin.

Method Details {#sec4.4}
--------------

### Methods: mouse {#sec4.4.1}

#### Cell preparations {#sec4.4.1.1}

Spleens were minced and digested with collagenase D (1 mg/mL) and DNase I (20 μg/mL) in full DMEM for 30 min at 37°C. Tissues were pressed through a nylon 70 μm cell strainer to yield single-cell suspensions and then subjected to red blood cell (RBC) lysis (155 mM NH~4~Cl, 10 mM NaHCO~3~, 0.1 mM EDTA) for 5 min at room temperature before being filtered. Bone marrow (BM) was prepared by flushing femurs and tibias with phosphate buffer saline (PBS) using a 27-gauge needle followed by RBC lysis and filtering through a sterile 70 μm cell strainer. Peripheral blood (PB) was obtained by submandibular bleed and subjected to RBC lysis for 5 minutes, followed by 3 min, at room temperature (RT).

#### Flow cytometry {#sec4.4.1.2}

Single-cell suspensions of cultured DCs or primary cells were stained for multicolor analysis with the indicated fluorochrome- or biotin-conjugated antibodies. Antibodies were diluted in FACS buffer (PBS, 1% FCS, 0.02% NaN~3~). With the exception of Hoxb8-derived DCs, staining of surface molecules with fluorescently labeled antibodies was performed for 20 min at 4°C in the dark. Hoxb8-derived DCs were stained at room temperature. For *in vivo* cross-presentation experiments, the OVA peptide/H-2K^b^ tetramer was used and staining was performed for 30 min at room temperature. Samples were acquired on LSR II (BD) flow cytometer using FACSDiva software (BD Biosciences) or Attune NxT (Invitrogen) using Attune NxT software and further analyzed with FlowJo software (Tree Star).

#### FLT3L-driven DC differentiation of Hoxb8-FL cultures {#sec4.4.1.3}

Hoxb8-FL progenitor cells were expanded in culture and differentiated as previously described ([@bib15], [@bib42]). Briefly, progenitor cells were removed from β-estradiol-supplemented medium and washed three times in PBS with 10% charcoal-stripped FBS at room temperature. The cells were then plated in fresh medium without estradiol at 2x10^5^ cells per well in 6-well plates and cultured for 7 days without replating.

#### Notch-driven DC differentiation of Hox8-FL cultures {#sec4.4.1.4}

FLT3L-driven Hoxb8-FL DC differentiation was initiated as described above. On day 3 of differentiation, cells were harvested and resuspended in fresh medium. The cells were then plated at 2.5x10^5^ cells per well in 24-well plates containing a monolayer of mitomycin-treated OP9-DL1 cells. Where indicated, control OP9-GFP or OP9-DL4 cells were used in a similar fashion. For NOTCH2 blocking experiments, cells were treated with anti-NOTCH2 antibody or control IgG (50 ng/mL or 500 ng/mL) on day 3 at the time of co-culture initiation. Cell cultures were analyzed by flow cytometry on day 7.

#### FLT3L-driven DC differentiation of primary BM cultures {#sec4.4.1.5}

Single cell suspensions of primary murine BM cells were obtained as described above. The cells were suspended in DMEM medium supplemented with 10% FCS, 1% L-glutamine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin, 55 μM 2-mercaptoethanol and, 10% supernatant from cultured B16-FLT3L cell line (DC medium). Cells were plated at 2x10^6^ cells per well in 2 mL of DC medium in 24-well plates and cultured at 37°C in a humidified atmosphere at 5% CO~2~ for 7 days without replating.

#### Notch-driven DC differentiation of primary BM cultures {#sec4.4.1.6}

Primary BM cultures were initiated as described above. On day 3 of differentiation, half of the volume of cells in DC medium from each well was transferred to a single well containing a monolayer of mitomycin-treated OP9 cells in 24-well plates. Where indicated, control OP9-GFP or OP9-DL4 cells were used in a similar fashion. For NOTCH2 blocking experiments, cells were treated with anti-NOTCH2 antibody or control IgG at various concentrations on day 3 at the time of coculture initiation. Cell cultures were analyzed on day 7.

#### *In vitro* DC migration assay {#sec4.4.1.7}

DC migratory capacity was evaluated using a transwell assay using 24-well plates of 6.5 mm transwells with 5.0 μm pore polycarbonate membrane (Corning). Cultured DCs were harvested on day 7 and resuspended in DMEM medium supplemented with 2% FCS, 1% L-glutamine, 1% sodium pyruvate, 1% MEM-NEAA and 1% penicillin/streptomycin (migration medium) at 5 × 10^5^ cells/ml. Migration medium containing chemokines (100 ng/mL in 0.6 mL total volume) was placed at the bottom of each well. DC suspension (100 μL) was added to the top chamber and incubated at 37°C in a humidified atmosphere at 5% CO~2~ for 3 hr. Migrated cells at the bottom of the wells were recovered in 500 μL of cold PBS supplemented with 2% FBS and 0.5 mM EDTA and analyzed by flow cytometry. For each DC type, frequency of migrated cells was calculated as \# cells migrated out of total input per DC type as determined flow cytometry.

#### *In vitro* T cell stimulation {#sec4.4.1.8}

Endotoxin-free chicken ovalbumin (OVA) protein (Sigma Aldrich) was added to DC cultures on day 7 to a final concentration of 100 μg/ml. Cells were then harvested, washed three times with PBS and filtered using sterile 70 μm cell strainers. Single cells suspensions were obtained from the spleens and lymph nodes of Rag2/OT-I mice as described above. CD8^+^ T cells were isolated by magnetic-activated cell separation (MACS) by negative selection using biotinylated antibodies (B220, Ter119, Gr1, CD11c, NK1.1, F4/80, CD4, DX5) with streptavidin microbeads, and MACS columns (Miltenyi Biotec). CD8^+^ T cells were stained with carboxyfluorescein succinimidyl ester (CFSE, 5 μM), washed and 4x10^4^ T cells were cultured with DCs at 1:1-10:1 ratio for 3 days. T cell proliferation was assessed by CFSE dilution using flow cytometry.

#### *In vivo* cross presentation assay {#sec4.4.1.9}

DC cultures were pulsed with endotoxin-free OVA protein for 2 hr as above. Cells were pooled, harvested, washed three times with PBS and filtered twice using sterile 70 μm cell strainers. To enrich cDC1, cells were stained with biotinylated antibodies against B220 and CD172a (FL cultures) or B220 and CD11b (FL+Notch cultures), and purified by negative selection on MACS columns. OVA-pulsed total DCs (2.5x10^5^ - 1x10^6^) or OVA-pulsed enriched cDC1 (3x10^5^) were resuspended in 0.1 mL PBS and injected i.v. into the retroorbital sinus. Spleens were harvested or PB was collected and analyzed by flow cytometry using OVA peptide/H-2K^b^ tetramer staining 7 days after DC vaccination.

#### Tumor challenge {#sec4.4.1.10}

B16-OVA melanoma cells were harvested, washed twice with PBS, and filtered. A total of 2.5x10^5^ B16-OVA cells in 0.1 mL PBS were injected i.v. into the retroorbital sinus 7-10 days following vaccination with OVA-pulsed DCs. Mice were monitored daily and sacrificed when moribund or on day 25 of observation if healthy. Lungs from perfused mice were harvested, fixed in 4% paraformaldehyde for 24 hr, sectioned and stained with hematoxylin/eosin for histological examination using light microscopy. Where indicated, 4x10^5^ B16-OVA cells in 0.2 mL PBS were injected i.v. into the tail vein.

#### Cell sorting and sample preparation for RNA-seq {#sec4.4.1.11}

DC populations were stained and sorted on BD FACSAria II as follows: cDC1 (CD11c^hi^ MHCII^+^ B220^−^ CD24^+^) and cDC2 (CD11c^hi^ MHCII^+^ B220^−^ CD11b^+^). Sorted cells (1--3x10^5^) were resuspended in 750 μL Trizol LS (Invitrogen), and RNA was extracted using the Arcturus PicoPure kit (Thermo Fisher Scientific). Equal volume of 70% ethanol was added to the aqueous phase of TRIzol samples and applied to columns from the PicoPure kit. Up to 250 μL of ethanol/aqueous phase mix was loaded onto the column and spun at 100 *g* for 2 min for each load. Bound RNA was washed, treated with DNase I (QIAGEN), and eluted as per manufacturer's instructions. To remove phenol contamination, eluate was resuspended in 100 μL of Wash Buffer 1 and reloaded onto a fresh column followed by elution. RNASeq libraries were prepared using the Clontech Ultra low RNA kit, starting with 3 ng, with 10 cycles of PCR for cDNA amplification, and the Clontech Low Input Kit for library prep, with 7 cycles of PCR amplification, following the manufacturer's protocol. The amplified library was purified using AMPure beads, quantified by Qubit and QPCR, and visualized in an Agilent Bioanalyzer. The libraries were pooled equimolarly, and run on a HiSeq 2500 as paired, 50 nucleotide in length.

#### RNA-Seq data processing {#sec4.4.1.12}

Sequencing reads were mapped to the mouse reference genome (GRCm38.85/mm10) using the STAR aligner (v2.5.0c) ([@bib10]). Alignments were guided by a Gene Transfer Format (Ensembl GTF GRCm38.85). The mean read insert sizes and their standard deviations were calculated using Picard tools (v.1.126) (<http://broadinstitute.github.io/picard/>). The read count tables were generated using HTSeq (v0.6.0) ([@bib2]), normalized based on their library size factors using DESeq2 (v3.0) ([@bib26]), and differential expression analysis was performed. The Read Per Million (RPM) normalized BigWig files were generated using BEDTools (v2.17.0) ([@bib40]) and bedGraphToBigWig tool (v4), and downstream statistical analyses and generating plots were performed in R environment (v3.1.1) (<http://www.r-project.org/>).

### Methods: human {#sec4.4.2}

#### Cell isolation, flow cytometry and cell sorting {#sec4.4.2.1}

Peripheral blood or bone marrow mononuclear cells (PBMC) were isolated by density centrifugation. For flow cytometry or fluorescence-activated cell sorting (FACS) (purity \> 98%), cells were stained in aliquots of 1-3 x10^6^ cells/50 μl of Dulbecco's phosphate-buffered saline with 0.1%--2% fetal calf serum and 0.4% EDTA. Dead cells, usually \< 5%, were excluded by DAPI (Partec) or Zombie (Biolegend) staining. Analysis was performed with an LSRFortessa X-20 and sorting with a FACSAria III (BD Biosciences) running BD FACSDIVA 8.0.1 or 8.0 software, respectively. Data were processed with FlowJo 10.4.1 (Treestar, Inc). Intracellular staining was performed after surface staining, lysis, and fixation (eBioscience) according to manufacturer's instructions.

#### *In vitro* generation of dendritic cells {#sec4.4.2.2}

FACS-purified CD34^+^ bone marrow progenitors were cultured (typically 3000/well) in 96 well U-bottomed plates with or without pre-seeded OP9, OP9-DL1 or OP9-DL4 stromal cells (5000/well). Culture media consisted of 200 μL α-MEM (GIBCO) supplemented with 1% penicillin/streptomycin (Sigma), 10% fetal calf serum (GIBCO), 20 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D systems), 100 ng/ml FLT3-ligand (FL, Immunotools), 20 ng/ml stem cell factor (SCF, Immunotools). Half the volume of media, with cytokines, was replaced weekly. At day 14 or 21, cells were harvested on ice, passed through a 50 μm filter, washed and stained for flow cytometric analysis or cell sorting. Cell output was normalized to 3000 input progenitors per well.

#### Dendritic cell functional analysis {#sec4.4.2.3}

For cytokine production, PBMC from healthy controls or *in vitro*-generated cells were cultured in the presence of polyinosinic:polycytidylic acid (poly(I:C), 10 μg/ml, Invivogen), Lipopolysaccharide (LPS, 5ng/ml, Sigma), CL075 (1 μg/ml, Invivogen) and CpG (ODN 2216, 7.5 μΜ, Invivogen) for 14h at 37°C, 5% CO~2~ with addition of Brefeldin A (10 μg/ml, eBioscience) after 3 hr. Dead cells (usually \< 30%) were excluded with Zombie amine dye (Biolegend). Intracellular cytokine staining was performed after surface staining, fixation, and permeabilization (eBIoscience) according to manufacturer's instructions.

For T cell proliferation, FACS-purified *ex vivo* or *in vitro* generated DCs (2,500-8,000 DC/well) were cultured with FACS purified allogeneic CD3^+^ T cells at a ratio of 1:10 DC:T cell (n = 2-9 DC/T cell pairs). Positive controls were generated by T cell co-culture with CD3+CD28+ beads (Dynabeads®, Thermo Fisher Scientific) at T cell:bead ratio 1:1. T cell proliferation was assessed by CFSE dilution on day 5 of culture.

#### NanoString nCounter Gene expression analysis {#sec4.4.2.4}

*Ex vivo* or culture-generated DCs were FACS purified (\> 98% purity) and lysed in RLT buffer containing 1% β-mercaptoethanol, at a concentration of 2000 cells/μl. Samples were analyzed on the NanoString nCounter® FLEX platform according to manufacturer's instructions. Briefly, 5 μl of lysate (10,000 cells) was mixed with reporter probes, hybridization buffer, and capture probes and hybridized at 65°C for 12-30 hr. Samples were then processed on the NanoString Prep station and cartridges were read on the NanoString Digital Analyzer to yield a reporter code count (RCC) dataset. The human Immunology_V2 panel was used, supplemented with the following 30 genes: *ASIP, DAXX, MERTK, C19orf59, DBN1, Ki67, CCL17, F13A1, NDRG2, CD1c, FGD6, PACSIN1, CD207, FLT3, PPM1N, CLEC10A, GCSAM, PRAM1, CLEC9A, GGT5, S100A12, CLNK, LPAR2, TMEM14A, COBLL1, LYVE1, UPK3A, CXCL5, MAFF, ZBTB46.*

Counts were normalized within the nSolver software (advanced analysis module version 1.1.4). The log2 transformed output data were analyzed using R (version 3.3.3). For principal component analysis (PCA), genes expressed below 2^4.8^ in all samples were removed (167/608). A culture signature was derived by performing pairwise comparisons (two-tailed t test with Benjamini-Hochberg correction of p values) of all culture versus all *ex vivo* populations. 102 genes with adjusted p values \< 0.05 (the culture signature) were excluded from further analysis. The remaining 339 genes were used to construct the PCA plot. Heatmaps were generated in R and display log2 transformed expression.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

For experimental results, all statistical calculations analysis were performed using Prism (GraphPad, La Jolla, CA). In animal experiments, statistical significance of differences between experimental groups was determined by non-parametric Mann-Whitney test. Differences in the Kaplan-Meier survival plots ([Figure 5](#fig5){ref-type="fig"}) were analyzed using log-rank test. In human cell culture experiments, statistical significance of differences between experimental groups was determined by unpaired, two-tailed Student's t test.

For RNA-seq data, Wald test p values and adjusted p values provided by DESeq2 package were used for differential expression analysis (adjusted p \< 0.1, FC \> 2) which is based on estimating dispersions and uses a negative binomial generalized linear model. For sample clustering, we performed a classical multidimensional scaling (MDS) and a Euclidean distance based clustering. For pathway and enrichment analysis, we used hypergeometric distribution tests performed by clusterProfiler package (adjusted p \< 0.1). The datasets were individually and comprehensively analyzed and visualized all in the R statistical environment (v3.2.5).

Data and Software Availability {#sec4.6}
------------------------------

The complete processed expression data from RNA-seq and Nanostring experiments are attached as [Tables S1](#mmc2){ref-type="supplementary-material"} and [S5](#mmc6){ref-type="supplementary-material"}, respectively. The accession number for the raw RNA-seq sequencing data reported in this paper is GEO: [GSE110577](ncbi-geo:GSE110577){#intref0085}.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S5Table S1. Gene Expression in DC Subsets as Determined by RNA-Seq and Used for Multidimensionality Scaling Analysis, Related to Figures 3A and S3AThe table includes log~2~-transformed normalized expression values in sorted cDC1 and cDC2 from FL or FL-Notch cultures (this study) or from primary splenic cDC1, cDC2 (Esam^hi^) and cDC2 (Esam^lo^) ([@bib22]).Table S2. Differential Gene Expression in DC Subsets from FL or FL-Notch Cultures, Related to Figure 3BShown is DeSeq2-generated lists of differentially expressed genes in cDC1 and cDC2 subsets from the two culture conditions.Table S3. The Expression of Notch Target Genes in DC Subsets, Related to Figures 3C and S3BData represent the same samples as in Table S1. The table includes log~2~-transformed normalized expression values for the genes that were differentially expressed in *Notch2*-deficient splenic DC as determined by the analysis of microarray data from ([@bib45]), including genes that were preferentially affected in cDC1, cDC2 or both subsets.Table S4. The Expression of Chemokine and Chemokine Receptor Genes in DC Subsets, Related to Figures 4B and S3CData represent the same samples as in Table S1.Table S5. Gene Expression Data from Human Blood- and Culture-Derived DC Subsets, Related to Figures 6 and S5DC were sorted from the peripheral blood or from cultures of CD34^+^ progenitors with OP9 or OP9-DL1, and gene expression analyzed on the NanoString nCounter platform running Human Immunology_V2 panel plus 30 genes (detailed in methods). The Table includes log~2~-transformed normalized expression values. Genes expressed at a low level (\< 2^4.8^) in all samples are listed separately; these were removed before the principal component analysis.Document S2. Article plus Supplemental Information
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